rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
about
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerUnderstanding and altering cell tropism of vesicular stomatitis virusOncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancerPotential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primatesExperimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells.Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment.Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.Curative one-shot systemic virotherapy in murine myeloma.Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Vesicular stomatitis virus as a treatment for colorectal cancerMyeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neckReplicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cellsConstrained evolvability of interferon suppression in an RNA virus.Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cellsSTAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideReview: Oncolytic virotherapy, updates and future directions.Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Oncolytic virotherapy in upper gastrointestinal tract cancers.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Reverse Genetics of Rhabdoviruses
P2860
Q27021839-68CF180C-D709-4725-8B27-93D6F0B3E864Q27687067-076A1C16-316C-46B2-A6B3-A8102FB83A4BQ28078939-B4C5BF1D-F5DF-4374-93B2-6748288F33C4Q33579385-CAD2B182-D4C9-4564-8ACC-F0F097DECEC6Q33635033-20EBECBE-97E5-4E33-8E84-01ACBF635264Q33832168-E1503005-6039-4DD4-8B2E-C72A62361351Q33882758-82504996-35D6-4897-BDB8-2856C40A0B49Q34262131-350325A3-7DC8-4C45-B9B5-F8EA68C26D2BQ34774805-AB18AE8D-25CB-42D9-AE3B-6D6933485ED4Q35275179-596E7493-AFBE-4CCF-81D7-A2979684773DQ36049446-A3629DCA-4679-4BEB-BB11-B4550B9EC2EBQ36139716-9ED64192-234C-4CE9-B5E2-8937DB6575AEQ36667968-F87E471E-4A2E-4C12-9033-D3D007A8F44AQ36751597-E1C6EF47-4318-4580-AB43-AE16962236E1Q36928614-61BFA257-BDA6-445F-AEA8-16B7F79AD076Q37100179-A3B0F5D2-819D-43CD-8ADC-BC8CE1BA6B12Q37123143-8F455420-9BB9-4042-991A-87B0C3BAD5A7Q37200546-7E081BC8-A3B3-480E-A5A2-E22AE96AB46BQ37564490-B009F886-756D-47E6-AB14-70A888505CAEQ37672599-4EDB6069-CDB9-4F9D-B8A7-FCC8E4ED9411Q37933439-AB9F1332-5B6C-4BB7-832B-4BA3AEF05476Q38209337-E81080D9-FC31-415E-914E-7930D4E1F314Q38746434-96A50AE3-734C-4058-A81A-6C1EB7913FCEQ38776765-069CBBA6-1056-47C4-AE38-D4AFA630B701Q39224943-4DCF18AD-A53D-4F7A-84D9-9D315D7E8FE9Q39413447-4C8B6300-49E4-4EDC-BADC-B222B4F2A18FQ39776032-7467C52C-9B11-4738-8087-7A07F158969AQ42144822-BBA42E59-1273-4305-8E68-D73C8ACCDF7FQ42157100-4CDBB5B2-C075-4C9F-85AE-7829C2CF10FBQ47160989-7B9FF78A-3C6F-40D2-9CD2-961BFE4FE3DEQ52688581-8C8B2FD0-C8E3-4222-BEB3-1216E187261AQ54242367-A6004B84-F318-4F88-9E0F-8E3255E7CCC2Q54378300-FD4A4D1E-7F73-439D-9339-5038E1ACC798Q57077874-2338D898-C9FA-4181-A34F-3472923AED16
P2860
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
rVSV
@nl
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
@en
type
label
rVSV
@nl
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
@en
prefLabel
rVSV
@nl
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
@en
P2093
P2860
P50
P356
P1433
P1476
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
@en
P2093
John Mandeli
Katsunori Shinozaki
Marcia Meseck
Oliver Ebert
Savio L C Woo
Tian-gui Huang
P2860
P304
P356
10.1089/HUM.2007.163
P577
2008-06-01T00:00:00Z